Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Current Assets (2016 - 2025)

Historic Current Assets for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $698.4 million.

  • Ani Pharmaceuticals' Current Assets rose 3397.39% to $698.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $698.4 million, marking a year-over-year increase of 3397.39%. This contributed to the annual value of $527.7 million for FY2024, which is 151.36% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Current Assets stood at $698.4 million, which was up 3397.39% from $602.6 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Current Assets ranged from a high of $698.4 million in Q3 2025 and a low of $182.8 million during Q1 2021
  • Moreover, its 5-year median value for Current Assets was $459.3 million (2023), whereas its average is $420.5 million.
  • Per our database at Business Quant, Ani Pharmaceuticals' Current Assets soared by 8892.27% in 2021 and then crashed by 78.94% in 2025.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Current Assets stood at $321.8 million in 2021, then increased by 6.99% to $344.3 million in 2022, then surged by 50.99% to $519.8 million in 2023, then grew by 1.51% to $527.7 million in 2024, then surged by 32.35% to $698.4 million in 2025.
  • Its last three reported values are $698.4 million in Q3 2025, $602.6 million for Q2 2025, and $536.3 million during Q1 2025.